India Rifampicin Market to Grow with a CAGR of 5.10% through 2030
High Tuberculosis (TB) Burden and Strong Demand for Fixed-Dose
Combination (FDC) Therapies is expected to drive the India Rifampicin Market
growth in the forecast period, 2026-2030
According to TechSci Research report, “India Rifampicin
Market – By Region, Competition, Forecast & Opportunities, 2030F”, the India
Rifampicin Market stood at USD 540.24 Million in 2024 and is anticipated to
grow with a CAGR of 5.10% in the forecast period, 2026-2030.
India is a global leader in the manufacturing of
active pharmaceutical ingredients (APIs), with the country's pharmaceutical
industry significantly expanding its rifampicin production capabilities.
Prominent Indian companies such as Lupin, Macleods Pharmaceuticals, and Cadila
Pharmaceuticals are making substantial investments in state-of-the-art
manufacturing facilities to enhance production capacity and ensure a reliable
supply. Furthermore, the growing export demand from high tuberculosis
(TB)-burden countries in Africa and Southeast Asia positions Indian
manufacturers to effectively tap into lucrative international markets.
In terms of government support, India has introduced
several initiatives, including the Production-Linked Incentive (PLI) Scheme for
Pharmaceuticals, aimed at reducing reliance on imported APIs and strengthening
domestic manufacturing. This aligns with the country’s broader objective of
achieving self-sufficiency in essential medicines, including rifampicin. Price
controls and subsidies under the National List of Essential Medicines (NLEM)
further facilitate affordability, driving market expansion.
Beyond TB, rifampicin is also used in the treatment of
leprosy, Legionnaire’s disease, and prosthetic joint infections, broadening its
potential market. Additionally, the rise in drug-resistant bacterial infections
has led to increased off-label use in hospital settings, creating additional
avenues for demand growth.
Browse over XX market data Figures spread
through XX Pages and an in-depth TOC on "India Rifampicin Market”
The India Rifampicin Market is segmented into source, form,
route of administration, application, end user, regional distribution, and
company.
Based on its distribution channel, the offline
distribution segment has emerged as the predominant market leader, Rifampicin
is primarily prescribed for TB treatment, which is usually managed in clinical
settings. Public and private healthcare institutions are the main points of
access for TB drugs. Hospitals, particularly those under government-run
programs like the Revised National Tuberculosis Control Program (RNTCP), are
crucial in ensuring that patients receive the right treatment. These facilities
account for a large volume of rifampicin prescriptions and distribution, making
the offline channel the dominant mode for delivering the drug to patients.
Government programs aimed at eradicating TB, such as
the National TB Elimination Program (NTEP), play a significant role in the
distribution of rifampicin. These programs focus on offline distribution
through a network of healthcare centers, often in rural and underserved areas,
where access to online platforms is limited. Rifampicin is made available free
of charge or at subsidized rates, primarily through offline channels. In India,
pharmacies remain a trusted source for acquiring prescription medications like
rifampicin. Many patients, particularly in semi-urban and rural areas, still
prefer visiting physical pharmacies for prescriptions, especially when it
involves ongoing, long-term treatments like TB management. The widespread
presence of local drugstores facilitates easy access to rifampicin.
Major companies operating in India Rifampicin Market
are:
- Indian Drugs and Pharmaceuticals Ltd.
- Cadila Pharmaceuticals Limited
- Macleods Pharmaceuticals Ltd.
- Lupin Limited
- Concept Pharmaceuticals Ltd
- Novartis India
- Zydus Group
- Themis Medicare Ltd
- GSK plc.
- Taurus Laboratories Pvt. Ltd
Download Free Sample Report
Customers can also request for 10% free customization
on this report
“The India rifampicin market is poised for continued
growth, driven by the country’s high tuberculosis burden, ongoing government
initiatives, and advancements in pharmaceutical manufacturing. While the
offline distribution channel remains dominant, the rise of online platforms and
digital healthcare solutions presents emerging opportunities for market
expansion. Indian pharmaceutical companies, supported by government incentives
and global export demand, are well-positioned to strengthen their production capabilities
and expand their market reach. As the healthcare landscape evolves,
particularly with increasing focus on drug-resistant TB, the demand for
rifampicin is expected to remain robust, ensuring that India plays a critical
role in the global TB eradication efforts.,” said Mr. Karan Chechi, Research
Director of TechSci Research, a research-based management consulting firm.
“India Rifampicin Market, By Source (In-house,
Contract Manufacturing Organizations), By Form (Tablet, Capsule, Injection), By
Route of Administration (Oral, Intravenous), By Distribution Channel (Online,
Offline), By Application (Tuberculosis, Leprosy, Legionnaire's Disease,
Others), By End User (Adult, Paediatric), By Region, Competition, Forecast
& Opportunities, 2020-2030F”, has evaluated
the future growth potential of India Rifampicin Market and provides statistics
& information on market size, structure and future market growth. The
report intends to provide cutting-edge market intelligence and help decision
makers take sound investment decisions. Besides, the report also identifies and
analyzes the emerging trends along with essential drivers, challenges, and
opportunities in India Rifampicin Market.
Contact
TechSci Research LLC
420 Lexington Avenue, Suite 300,
New York, United States- 10170
Tel: +1-332-258-6602
Email: [email protected]
Website: www.techsciresearch.com